Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SH) has announced that it received the "Chemical Drug API Market Application Approval Notice" for Lenvatinib Mesylate from the National Medical Products Administration, granting approval for the drug's market application. This drug is a tyrosine kinase receptor (RTK) inhibitor, intended for the treatment of patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.